UBS AM’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-10,498
| Closed | -$308K | – | 2632 |
|
|
2017
Q3 | $308K | Buy |
10,498
+1,200
| +13% | +$33.6K | ﹤0.01% | 2071 |
|
|
2017
Q2 | $244K | Hold |
9,298
| – | – | ﹤0.01% | 2125 |
|
|
2017
Q1 | $218K | Buy |
+9,298
| New | +$229K | ﹤0.01% | 2150 |
|
|
2016
Q4 | – | Sell |
-15,098
| Closed | -$424K | – | 2793 |
|
|
2016
Q3 | $424K | Hold |
15,098
| – | – | ﹤0.01% | 2079 |
|
|
2016
Q2 | $372K | Hold |
15,098
| – | – | ﹤0.01% | 2123 |
|
|
2016
Q1 | $334K | Buy |
15,098
+2,600
| +21% | +$69.2K | ﹤0.01% | 2151 |
|
|
2015
Q4 | $437K | Hold |
12,498
| – | – | ﹤0.01% | 2124 |
|
|
2015
Q3 | $356K | Hold |
12,498
| – | – | ﹤0.01% | 2197 |
|
|
2015
Q2 | $416K | Buy |
12,498
+2,200
| +21% | +$67.5K | ﹤0.01% | 2157 |
|
|
2015
Q1 | $290K | Buy |
+10,298
| New | +$256K | ﹤0.01% | 2281 |
|
|
2014
Q3 | – | Sell |
-8,098
| Closed | -$232K | – | 2594 |
|
|
2014
Q2 | $232K | Hold |
8,098
| – | – | ﹤0.01% | 2334 |
|
|
2014
Q1 | $227K | Buy |
+8,098
| New | +$199K | ﹤0.01% | 2363 |
|
|
2013
Q4 | – | Sell |
-11,998
| Closed | -$159K | – | 2579 |
|
|
2013
Q3 | $159K | Hold |
11,998
| – | – | ﹤0.01% | 2393 |
|
|
2013
Q2 | $166K | Buy |
+11,998
| New | +$170K | ﹤0.01% | 2315 |
|
UBS AM's PMC Position: Q4 2017 in Review
UBS AM sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 10,498 shares — an estimated $308K sold.
UBS AM first reported a position in PMC in Q2 2013 and held it in 14 quarters. The position peaked at $437K in Q4 2015. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- UBS AM reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- UBS AM sold 10,498 PharMerica Corporation shares in Q4 2017, an estimated $308K.
- UBS AM first reported a position in PharMerica Corporation in Q2 2013 and held it in 14 quarters.
- UBS AM's PharMerica Corporation position peaked at $437K in Q4 2015.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on UBS AM's 13F filing for Q4 2017, filed 9 Feb 2018.